Of the strong candidates for GUV’s Deal of the Year, Lund and Edinburgh universities-founded drug developer Galecto Biotech sealed the award for a €79m ($90m) series C close that supplemented a promising set of clinical data for its lead candidate.
Mainland Europe is often said to be the problem child in the continent’s academic family when it comes to technology transfer, especially compared with the UK’s successes. And with dozens of spinouts being churned out by the golden triangle of London, Oxford and Cambridge alone, it is easy to assign some truth to such a statement.
Global University Venturing will reveal the winners of this year's awards at the gala dinner as part of GUV: Fusion on May 22.
Lessons from the GUV Summit in Houston, Texas, this month
The top 25: Jim Wilkinson, CFO, Oxford Sciences Innovation
Introducing the Global University Venturing Powerlist 2018